Presymptom Health has raised funds in a seed financing round to advance the development of its blood test for the early identification of sepsis.
The funds, from Ploughshare Innovations and UK Innovation & Science Seed Fund, will allow the government spin-out medical technology company to conclude clinical trials at various hospitals in the UK as well as progress the diagnostic test towards approval and launch.
The test is based on findings from more than ten years of research at the Defence Science and Technology Laboratory (Dstl).
